1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor (GIST) - Drugs In Development, 2022, provides an overview of the Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor (GIST) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 23, 21, 14, 4 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.
Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Gastrointestinal Stromal Tumor (GIST) - Overview
- Gastrointestinal Stromal Tumor (GIST) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development
- Gastrointestinal Stromal Tumor (GIST) - Drug Profiles
- Gastrointestinal Stromal Tumor (GIST) - Dormant Projects
- Gastrointestinal Stromal Tumor (GIST) - Discontinued Products
- Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, 2022
- Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, 2022
- Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AB Science SA
- ABL Bio Inc
- Advanced Accelerator Applications SA
- Advenchen Laboratories LLC
- Allarity Therapeutics Inc
- Alligator Bioscience AB
- Alyra Therapeutics Inc
- Arog Pharmaceuticals Inc
- Ascentage Pharma Group International
- Bayer AG
- BeiGene Ltd
- Beijing Immunochina Pharmaceuticals Co Ltd
- BioAtla Inc
- Blueprint Medicines Corp
- Calithera Biosciences Inc
- Clarity Pharmaceuticals Ltd
- Cogent Biosciences Inc
- CStone Pharmaceuticals Co Ltd
- DNAtrix Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Esperas Pharma Inc
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Hanmi Pharmaceuticals Co Ltd
- Hefei Cosource Pharmaceutical Inc
- Horizon Therapeutics Plc
- Hoth Therapeutics Inc
- Idera Pharmaceuticals Inc
- IDRx Inc
- ImmunityBio Inc
- Mendus AB
- Merck & Co Inc
- Merck KGaA
- NewBay Medical Technology Co Ltd
- Ningbo Tai Kang Medical Technology Co Ltd
- Novartis AG
- Novelty Nobility Inc
- Omeros Corp
- Pfizer Inc
- Pharma Mar SA
- Plexxikon Inc
- Protheragen Inc
- Qualigen Therapeutics Inc
- Sartar Therapeutics Ltd
- Shanghai Affinity Biomedical Technology Co Ltd
- Shanghai Haihe Biopharma Co Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- Shijiazhuang Yiling Pharmaceutical Co Ltd
- Soricimed Biopharma Inc
- Taivex Therapeutics Inc
- Takeda Pharmaceutical Co Ltd
- Theseus Pharmaceuticals Inc
- TotalClarity Inc
- Virocure Inc
